BioNTech stock
Price history
−17.20% over the period1 year: from $102.67 (November 17, 2025) to $85.02 (November 17, 2026), −17.20%.
Show chart data
Closing prices adjusted for splits: the last close of each month.
| Date | Close |
|---|---|
| November 17, 2026 | $85.02 |
| October 30, 2026 | $88.17 |
| September 30, 2026 | $98.30 |
| August 31, 2026 | $101.61 |
| July 31, 2026 | $90.58 |
| June 30, 2026 | $93.05 |
| May 29, 2026 | $95.95 |
| April 30, 2026 | $103.45 |
| March 31, 2026 | $88.88 |
| February 27, 2026 | $110.23 |
| January 30, 2026 | $113.75 |
| December 31, 2025 | $95.20 |
| November 28, 2025 | $103.15 |
| November 17, 2025 | $102.67 |
At a glance
The company
Develop and commercialize immunotherapies including mRNA vaccines and oncology drugs across multiple clinical trial phases
Latest results
Quarter to September 30, 2026 · EPS €1.76 (estimate €0.78)
TickerLandia's take on BioNTech
Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks
Where the price stands
−31.56% from the 52-week high
Analysts · 21 analysts
Average target$112.40+32.45% vs. price
Buy 14 · Hold 7 · Sell 0 · Buy
TickerLandia Fingerprint: BioNTech
Compared with similar companies: low price, weak momentum, and low profitability.
Financials and price compared with 61 companies in the biotechnology industry, worldwide. Momentum and risk compared with 883 North American stocks.
Pricelow25
How much it costs relative to what it produces.
Metric Value Position in group Price/book 1.07 4 Price/sales 8.77 46 Profitabilitylow27
How much it earns on revenue and capital.
Metric Value Position in group ROE −8.1% 26 ROA −4.0% 29 Net margin −60.9% 11 Gross margin 76.7% 53 Operating margin −55.4% 17 Earnings stabilityaverage46
How steady its margins were over the last five annual reports.
Metric Value Position in group Margin variabilitycounts in reverse: lower means more earnings stability 59.8% 39 Loss-making yearscounts in reverse: lower means more earnings stability 2 of 5 annual reports 53 Growthlow34
How fast revenue and earnings are growing.
Metric Value Position in group Average revenue growth (3 years) −45.06% 3 Earnings growth (year over year) +102.50% 86 Revenue growth (year over year) −15.10% 15 Financial strengthaverage57
How well it would weather a hard period: debt, liquidity, interest.
Metric Value Position in group Interest coverage −89.2 5 Current ratio 8.55 84 Debt/equitycounts in reverse: lower means more financial strength 0.02 81 Dividendno dividend
How much it returns to shareholders, and for how long.
Market momentumweak27
How the stock has moved compared with the market.
Metric Value Position in group Relative strength (3 months) −3.26% 39 Relative strength (6 months) −5.34% 32 1-year return −17.35% 14 Distance from 200-day average −11.12% 23 Riskaverage58
How much the price swings.
Metric Value Position in group Beta (1 year) 0.97 63 Volatility (60 days) 38.3% 59 Maximum drawdown (12 months) 29.7% 51
Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 18, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated
Valuation
BioNTech is cheaper than similar companies
BioNTech's Price/book: 1.07, −87% against the median of a group of 10 similar companies (8.03).
Compared with 11 similar companies
| Metric | BioNTech | Position in the group | Band |
|---|---|---|---|
| Operating margin | -55.4% | Low | |
| ROE | -8.1% | Middle | |
| Debt/equity | 0.02 | Low | |
| Price/book | 1.07 | Low | |
| Net margin | -60.9% | Low |
Grey band: the middle half of the group; tick: the median; dot: BioNTech. All multiples and dividends
TickerLandia analysisHow it is calculated
The financials
The business in numbers
Revenue
€105.6M
Latest quarter · Q2 2026
Net income
-€820.8M
Latest quarter · Q2 2026
Quarterly net margin
-777.3%
Latest quarter · Q2 2026
Numbers and valuation
Full valuation- Market cap
- $21.22B
- EPS
- -$6.83
- Volume
- 844.5K
- Daily trading
- €73.65M
How BioNTech is changing
All resultsRevenue grew 42.9% a year on average over the last 5 years
Operating margin fell from 68.8% to −44.1%
Profitable in 3 of 5 fiscal years
Returns
BioNTech returns with dividends
$1,000 invested in BioNTech 5 years ago, on November 17, 2021, would be worth $317 today with dividends reinvested: −68.32% in total, −20.54% per year. On price alone it would be $313 (−68.74%).
| Period | BioNTech | S&P 500 | $1,000 becomes |
|---|---|---|---|
| 1 month | −4.70% | −3.17% | $953 |
| 6 months | −5.24% | +0.11% | $948 |
| Year to date | −10.70% | +8.34% | $893 |
| 1 year | −17.20% | +11.15% | $828 |
| 3 years | −14.46% | +64.30% | $855 |
| 5 years | −68.32% | +58.18% | $317 |
Over the last 6 months it has done better than 16% of the stocks in the Healthcare sector.
From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment
The chart in detail
BioNTech: technical analysis
BioNTech is in a downtrend: the price is below its 50- and 200-session moving averages, and the 200-session average is falling. The price is 81.0% below its all-time closing high ($447.23, August 9, 2021).
- Trend
- Downward
- RSI (14 sessions)
- 39
- Between 30 and 70
- vs 200-session average
- −11.12%
Support and resistance
Price areas where BioNTech has stopped several times in the last year. They describe the chart; they are not forecasts.
- Resistance$90.97+7.20%4 touches, last on November 4, 2026
- Resistance$88.13+3.85%6 touches, last on October 16, 2026
- Resistance$84.91+0.06%3 touches, last on October 27, 2026
- Last price$84.86
- No support below: the price is near the lows of the year
Volatility and risk
Over the last year it has moved roughly in line with the S&P 500.
- Beta (1 year) vs S&P 500
- 0.97
- Volatility (60 sessions, annualised)
- 38.3%
- Largest fall in the last year
- −29.71%
Close of November 17, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it
BioNTech: seasonality
Average monthly price change over 7 years
Over the last 7 years, the strongest month for BioNTech has been November: +19.29% on average, positive in 6 years out of 7. The weakest has been February: −3.79% on average, positive in 1 years out of 7.
Show chart data
| Month | Average | Median | Positive years |
|---|---|---|---|
| January | +1.43% | −4.53% | 3 of 7 |
| February | −3.79% | −6.76% | 1 of 7 |
| March | +5.77% | +0.15% | 4 of 7 |
| April | +7.69% | −3.72% | 3 of 7 |
| May | +2.91% | +4.32% | 4 of 7 |
| June | +3.78% | +2.71% | 4 of 7 |
| July | +12.42% | +7.27% | 6 of 7 |
| August | −2.71% | +0.26% | 4 of 7 |
| September | +1.29% | −3.26% | 2 of 7 |
| October | +0.55% | +2.05% | 4 of 7 |
| November | +19.29% | +21.35% | 6 of 7 |
| December | −3.34% | −7.71% | 2 of 7 |
Price change only, dividends excluded. Past seasonality does not predict future moves.
The company
BioNTech and its competitors
The United States accounted for 62.5% of revenue in the fiscal year ended December 2025, ahead of Germany at 26.5% and Ireland at 10.6%. BioNTech SE, together with its subsidiaries, develops and commercializes immunotherapies, with its operations based in Germany. Its vaccine BNT162 is an mRNA product against SARS-CoV-2. The oncology pipeline includes drugs in Phase III trials, among them Gotistobart for metastatic non-small cell lung cancer and Pumitamig for small cell lung cancer, along with candidates for influenza, tuberculosis, malaria and mpox.
- Headquarters
- Mainz, Germany
- Employees
- 7,807
- Founded
- 2008
- Chief executive
- Ugur Sahin
| Company | Market cap | Operating margin | P/E (trailing 12 months) | 6 months |
|---|---|---|---|---|
| BioNTechBNTX | $21.22B | -55.4% | — | −5.24% |
| Alnylam PharmaceuticalsALNY | $22.11B | 19.5% | 8.34 | −45.47% |
| IncyteINCY | $24.36B | 32.2% | 61.0 | +24.95% |
| Ascendis PharmaASND | $18.06B | 30.9% | 18.1 | +12.76% |
| InsmedINSM | $26.96B | -41.7% | — | +11.65% |
| ExelixisEXEL | $16.37B | 40.2% | 20.1 | +36.64% |
Same industry or related industries, similar size. Compare BioNTech with its competitors · Full profile
